Catalog number : DIUR-500
Quantity: 500 tests
Availability: Yes

DESCRIPTION:
Urea is primarily produced in the liver and secreted by the kidneys. Urea
is the major end product of protein catabolism in animals. It is the
primary vehicle for removal of toxic ammonia from the body. Urea
determination is very useful for the medical clinician to assess kidney
function of patients. In general, increased urea levels are associated with
nephritis, renal ischemia, urinary tract obstruction, and certain extrarenal
diseases, e.g., congestive heart failure, liver diseases and diabetes.
Decreased levels indicate acute hepatic insufficiency or may result from
over-vigorous parenteral fluid therapy.
Simple, direct and automation-ready procedures for measuring urea
concentration or blood urea nitrogen BUN in biological samples are
becoming popular in Research and Drug Discovery. BioAssay Systems'
urea assay kit is designed to measure urea directly in biological samples
without any pretreatment. The improved Jung method utilizes a
chromogenic reagent that forms a colored complex specifically with urea.
The intensity of the color, measured at 520nm, is directly proportional to
the urea concentration in the sample. The optimized formulation
substantially reduces interference by substances in the raw samples.

KEY FEATURES:
Sensitive and accurate. Use 5 μL samples. Linear detection range 0.08
mg/dL (13 μM) to 100 mg/dL (17mM) urea in 96-well plate assay.
Simple and high-throughput. The procedure involves addition of a single
working reagent and incubation for 20 min. Can be readily automated as a
high-throughput assay for thousands of samples per day.
Improved reagent stability and versatility. The optimized formulation has
greatly enhanced reagent and signal stability. Cuvet or 96-well plate assay.
Low interference in biological samples. No pretreatments are needed.
Assays can be directly performed on raw biological samples i.e., in the
presence of lipid and protein.

APPLICATIONS:
Direct Assays: urea in serum, plasma, urine, milk, cell/tissue culture,
bronchoalveolar lavage (BAL) etc.
Drug Discovery/Pharmacology: effects of drugs on urea metabolism.
Environment: urea determination in waste water, soil etc.

KIT CONTENTS: (500 tests in 96-well plates)
Reagent A: 50 mL Reagent B: 50 mL
Urea standard: 1 mL 50 mg/dL
Storage conditions. The kit is shipped at room temperature. Store all
components at 2-8°C. For long-term storage, keep standard at –20°C.
Shelf life: 12 months after receipt.

Precautions: reagents are for research use only. Normal precautions for
laboratory reagents should be exercised while using the reagents.

 Price: 339 EUR

The BULLET BLENDER^® enables you to homogenize, disrupt, or lyse up to 24 tissue or cell culture samples at a time. Load the samples into standard polypropylene tubes, then place them in the BULLET BLENDER. The "bullets" in the instrument vigorously strike all of the tubes and homogenize your sample in minutes. The Bullet Blender is available with Air Cooling™ to preserve your sample quality!

Applications:

Homogenize Tissue
Liver, Spleen, Kidney, Brain, Adipose, Bladder, Eye, Thyroid, Gallbladder, Muscle, Pancreas, Testes, Meconium, Thymus

Homogenize Tougher Tissue
Heart, Aorta, Tumor, Tail Snips, Colon, Lung, Blood Vessel, Trachea, Cartilage, Epithelium, Stomach, Intestine, Larynx, Mouse Femur, Pharynx, Umbilical Cord, Skin, Uterus

Lyse Cells
E. coli, Mamallian cell culture, Yeast

Homogenize Plant Material
Leaves, Beans, Nuts, Roots

Homogenize Small Organisms
Zebrafish, Drosophila

Whole Cell Isolation
Bacteria, Lymphocytes, Blood Cells

Organelle Isolation
Nucleus, Mitochondria

Click here for more information

More form Gentaur: Order Beads for Bullet Blender

Researchers from the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research today unveiled the first-ever antimicrobial hydrogel that can break apart biofilms and destroy multidrug-resistant superbugs upon contact. Tests have demonstrated the effectiveness of this novel synthetic material in eliminating various types of bacteria and fungi that are leading causes of microbial infections, and preventing them from developing antibiotic resistance. This discovery may be used in wound healing, medical device and contact lens coating, skin infection treatment and dental fillings.

IBN Executive Director Professor Jackie Y. Ying said, “As a multidisciplinary research institute, IBN believes that effective solutions for complex healthcare problems can only emerge when different fields of expertise come together. Our longstanding partnership with IBM reflects the collaborative creativity across multiple platforms that we aim to foster with leading institutions and organizations. By combining IBN's biomaterials expertise and IBM’s experience in polymer chemistry, we were able to pioneer the development of a new nanomaterial that can improve medical treatment and help to save lives.”

Dr Yi-Yan Yang, Group Leader at IBN said, “The mutations of bacteria and fungi, and misuse of antibiotics have complicated the treatment of microbial infections in recent years. Our lab is focused on developing effective antimicrobial therapy using inexpensive, biodegradable and biocompatible polymer material. With this new advance, we are able to target the most common and challenging bacterial and fungal diseases, and adapt our polymers for a broad range of applications to combat microbial infections.”

More than 80% of all human microbial infections are related to biofilm. This is particularly challenging for infections associated with the use of medical equipment and devices. Biofilms are microbial cells that can easily colonize on almost any tissue or surface. They contribute significantly to hospital-acquired infections, which are among the top five leading causes of death in the United States and account for US$11 billion in healthcare spending each year.

Catalog number : ISB01L
Quantity: 1L
Availability: Yes
Details:

InstantBlue™
InstantBlue is the fastest ready-to-use stain available and been optimised to give well-defined protein bands in a single step.
Specially formulated for ultra-fast, sensitive and safe detection of proteins, staining takes minutes without the need to wash, fix, microwave or destain.
Other benefits include high sensitivity (as little as 5 ng per band with BSA - See FAQs), low background staining and non-toxic formulation.
Ultra-fast staining - providing results in 15 minutes or less.
Single step procedure - no need to wash, fix, microwave or destain. Just take the gel out of the cassette and place in a container with InstantBlue.
High sensitivity - approximately 5-25ng of protein detected per band.
Super-Low background staining - Improves overall gel resolution and sensitivity and no possibility of over staining means that you can leave your gel in the stain indefinitely and still be able to read it.
Quantitative - Same gel-to-gel performance ideal for quantifying protein by densitometry
Non-toxic - ideal for regular use and disposal.
Mass Spec Compatible.

Introduction:
InstantBlue™ is a ready-to-use, proprietary Coomassie® stain that is specially
formulated for ultra-fast, sensitive and safe detection of your proteins. Protein
gels can be stained in minutes without the need to wash, fix or destain.
Only proteins are stained resulting in well defined blue bands on a highly
transparent background. The reduction of background interference results in a
better signal to noise ratio and may also have a positive impact on the overall
resolution and sensitivity.
The InstantBlue formulation is non-toxic and does not contain any methanol.
Proteins stained using the InstantBlue stain are also compatible with mass
spectrometry (MS) analysis.

Contents:
1L reagent, containing Coomassie dye, ethanol, phosphoric acid and solubilizing
agents in water. (Caution: Phosphoric acid is a corrosive liquid.)

Storage:
Upon receipt store at + 4°C. Discard any reagents that show discoloration or
evidence of microbial contamination. Be sure to keep the bottle capped when not
in use.

 Price: 144 EUR

560 tubes of 15ml for only 25 Euro

440 tubes of 50ml for only 25 Euro

Bullous pemphigoid is a subepidermal blistering disorder associated with tissue-bound and circulating autoantibodies directed mainly to the hemidesmosomal component collagen XVII. While recapitulating the main immunopathological features of the human disease, frank skin blistering does not develop in the absence of skin rubbing in experimental pemphigoid models that have been established in neonatal mice.

Moreover, due to their experimental design they only allow for short-term disease observation. In the present study we aimed to establish a model that reproduces the frank skin blistering seen in patients and allows for longer observation times.

Methods: Rabbit and sheep antibodies specific to several fragments of collagen XVII were generated and the purified antibodies were passively transferred into adult mice.

Results: Collagen XVII-specific IgG bound to the basal membrane of the skin and mucous membranes activating murine complement in vivo.

Mice injected with collagen XVII-specific antibodies, in contrast to mice receiving control antibodies, developed frank skin blistering disease, reproducing human bullous pemphigoid at the clinical, histological and immunopathological levels. Titres of circulating IgG in the serum of mice correlated with the extent of the clinical disease.

Mice receiving sheep antibodies specific to murine collagen XVII showed an early onset and a more active disease when compared to litter mates receiving specific rabbit antibodies.

Conclusion: This novel animal model for bullous pemphigoid should facilitate further investigations of the pathogenesis of bullous pemphigoid and the development of innovative therapies for this disease.

TARGATT Fast & Efficient Gene Modification in Human Cells. Make your cell line in 3 months!

• - Efficient insertion of any gene
• - Single-copy
• - Stable expression
•  
•  Click here to see all products
•  

Based on our proprietary site-specific TARGATT technology for fast knock-in mouse (KI) generation, Applied StemCell Inc. (ASC) recently developed a TARGATT system specifically for introducing gene(s) of interest into mammalian cell lines. The unique advantage of this system is that any gene of interest can be inserted efficiently into a defined, transcriptionally-active locus with high gene expression in a single copy fashion.

Technical Details:

TARGATT technology enables highly efficient site-specific gene integration in mammalian cells and animals1, 2. This technology uses ?C31 integrase to insert any gene of interest into a docking site, pre-engineered in an intergenic region and transcriptionally active genomic locus. Our TARGATT technology improves several aspects in the generation of transgenic cell lines and animals: (1) High integration efficiency mediated by ?C31 integrase reduces time and cost; (2) Site-specific integration at a pre-selected genomic locus eliminates position effect and ensures high level expression of the transgene; (3) Integration at intergenic region ensures that no internal genes are interrupted; (4) Single copy gene integration eliminates repeat-induced gene silencing and genomic instability; (5) Site-specific integration allows a precise comparison of the effects of the transgenes among different lines. TARGATT technology can be utilized for a variety of applications including reporter gene expression, gene knockdown, disease cell and animal models.

More information - PDF presentation

More information about Stem cells

Prices

Millions of lives have been changed over the past fourthy years because of advances in medical technology. From stem-cell research to reengineering the way we take our daily medications, all these developments have brought health care into the 21st century. There has been a vast disconnect between these improvements and the manufacturing processes used to provide influenza vaccines to the public.

Shockingly, the method used to produce the influenza vaccine has not been significantly transformed since 1931, when vaccines used for preventive care were first introduced to the public.

Influenza causes between 3,000 and 48,000 deaths and 190,000 hospitalizations in any given season, so it is critical to utilize the most effective production methods to create influenza vaccines to protect our communities. Until recently, all influenza vaccines available in the U.S. were produced by growing and harvesting the virus in chicken eggs. During the time this method has been successful, millions of eggs are needed to produce enough vaccine for our communities each year, requiring production to begin many months in advance. Once the virus strains are selected for the upcoming influenza season by the WHO (World Health Organization), and companies begin manufacturing the vaccine, it can take anywhere between 6 and 9 months to make the vaccine available to physicians or pharmacists.

The egg-based manufacturing process has been working for us to date; however, there is a new process that raises the bar in influenza vaccine manufacturing, is less time-consuming and brings the manufacturing process into the digital age.

Cell-culture technology is the latest production technique for influenza vaccine manufacturing, which involves growing the virus in cells from mammals, rather than chicken eggs. This method offers advantages over the conventional egg-based process:

• Since no eggs need to be collected, vaccines can be produced and available to the public quicker, which is critical in case of a flu pandemic.

• The process does not use any preservatives or antibiotics during production.

Cell-culture technology has been successfully used to manufacture many other vaccines, including those distributed during the H1N1 pandemic, as well as vaccines for polio, rubella and hepatitis A. This technology also has been tried and tested in other countries, which have already approved and use cell-based influenza vaccines abroad. Recently, the FDA gave its stamp of approval to use the technology in influenza vaccines available in the U.S., with an approval of a cell-based seasonal influenza vaccine.

It is important that such a fundamental vaccine that every American ages 6 months and older is advised to receive each year is available using the most cutting-edge technology. I am excited to see how this major advancement will help start a new chapter in the evolution of influenza prevention.

In an approach with the potential to aid therapeutic vaccine development, Whitehead Institute scientists have shown that enzymatically modified antibodies can be used to generate highly targeted, potent responses from cells of the immune system.

The approach, referred to as "sortagging," relies on the bacterial enzyme sortase A to modify antibodies to carry various payloads, such as peptides, fluorophores, lipids, fluorophores, and proteins. In this case, the scientists, whose findings are reported online this week in theProceedings of the National Academy of Sciences, attached a variety of small antigens to an antibody directed at the surface of key immune cells. Through sortagging, the scientists were quickly able to prepare various antibody-antigen fusions and to deliver the antigens to their intended targets and track them as the immune cells mounted their intricate responses.

"Sortagging is remarkably specific and efficient," says Lee Kim Swee, a researcher in the lab of Whitehead Member Hidde Ploegh. "We were able to create 50 different constructs (antibody-protein attachments), which wouldn't have been feasible if we had relied on the more traditional approach of genetic fusion."

Swee and colleagues tested the approach in a mouse model of herpes virus, sortagging 19 known viral epitopes to a cell-specific antibody. They created a vaccine cocktail and immunized a group of mice. Upon subsequent re-exposure to the virus, vaccinated mice showed a 10-fold reduction in the amount of circulating virus.

"This is proof of principle that one could in fact use sortagging on antibodies to easily attach a tailored set of antigens, toward which the immune system can be educated," Swee says. "This technique also helps us understand how to design better antibody-based vaccines."

For paper co-author Carla Guimaraes, sortagging's value is bolstered by its flexibility. She likens it to "playing with Legos," because it allows "you to mix and match" proteins of diverse shapes, sizes, and functions. The process can be used, for example, to attach the relatively large green fluorescent protein (GFP) to antibodies without hindering GFP's desirable fluorescing activity or the binding of the conveying antibody to its intended target.

"Imagination is really your only limitation," says Guimaraes, who is also a postdoctoral researcher in the Ploegh lab. "You could for example, use sortase to attach a toxin to an antibody and use that antibody to deliver the toxin to specific cells." Such an approach, she notes, would be an appealing strategy for developing better-tolerated cancer therapies.

Hidde Ploegh's primary affiliation is with Whitehead Institute for Biomedical Research, where his laboratory is located and all his research is conducted. He is also a professor of biology at Massachusetts Institute of Technology.

Further research conducted for the annual 2013 Cell Line Development & Engineering conference in Vienna next February, showed major developments in cell culture systems have given biotech's and pharmaceutical companies more flexibility to scale up cells to a high manufacturing quality.The production of high-performing cell lines have been enabled by cell engineering tools and this has only been possible through improvements in cell culture media.

For best accommodation of these new developments, Informa Life Sciences' have expanded the programme to cover the latest in cell line development strategies and improvements in cell culture systems. Alison Porter, Head of Cell Line Development in the Mammalian Cell Culture group at Fujifilm Diosynth Biotechnologies (FFDB) clarifies how "For first in human studies with cell line construction on the critical path, it is vital to have optimised the early stages of cell line development. This can improve the future success of a biotherapeutic, both in terms of having the 'best' cell line and meeting increasingly tight timelines."

Further feedback from over 50 industry professionals and academics also highlight additional trends such as high throughput screening of cell lines, Quality by Design applications, cell line development strategies for novel products, analytical tools for product evaluation and bioinformatics applications.

Informa's annual 2013 Cell Line Development & Engineering conference has been designed to address topics essential to improve product development and quality. Susanna Benaim Conference Producer at Informa Life Sciences explains "The event uncovers the essentials in micro-scale system application, CHO genome sequencing, cell line engineering and targeted integration. The conference brings together leading experts from protein engineering, cell biology, cell line development and bioprocess, from both the pharmaceutical industry and academia. Any company specialising in this area is encouraged not to miss out."